These Analysts Boost Their Forecasts On Adobe After Upbeat Earnings

Adobe Inc. (NASDAQ:ADBE) posted upbeat results for its second quarter and also issued a strong forecast. Adobe reported…

Adobe Inc. (NASDAQ:ADBE) posted upbeat results for its second quarter and also issued a strong forecast.

Adobe reported second-quarter revenue of $5.31 billion, beating the consensus estimate of $5.292 billion. The company reported quarterly adjusted earnings of $4.48 per share, beating analyst estimates of $4.39 per share, according to data from Benzinga Pro.

“Adobe achieved record revenue of $5.31 billion driven by strong growth across Creative Cloud, Document Cloud and Experience Cloud,” said Shantanu Narayen, chair and CEO of Adobe.

Adobe expects third-quarter revenue to be in the range of $5.33 billion to $5.38 billion versus estimates of $5.03 billion. The company anticipates third-quarter adjusted earnings of $4.50 to $4.55 per share versus estimates of $4.17 per share.

Adobe also introduced full-year 2024 guidance. The company expects full-year revenue to be between $21.4 billion and $21.5 billion versus estimates of $19.98 billion. Adobe sees full-year adjusted earnings in the range of $18 to $18.20 per share versus estimates of $16.78 per share, according to Benzinga Pro.

Adobe shares fell 0.3% to close at $458.74 on Thursday.

These analysts made changes to their price targets on Adobe after the company reported quarterly results.

  • Keybanc increased the price target on Adobe from $445 to $450. Keybanc analyst Jackson Ader maintained an Underweight rating.
  • Baird raised Adobe price target from $525 to $545. Baird analyst Rob Oliver maintained a Neutral rating.

Read More: Top 2 Materials Stocks That May Collapse This Quarter

Total
0
Shares
Related Posts
Read More

Pharma Mafia Wants To Conquer Cannabis: Can You Patent A Plant? Jazz Is Trying

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) recently published collected data on CBD safety, placing the information under its Yellow Card alert system, which lists various adverse reactions to drugs in general. In the report, the agency notes that as many as 10 people have died from CBD and more than 870 experienced adverse reactions.

ACB